Actuate Therapeutics (NASDAQ:ACTU) Trading 0.8% Higher – Here’s What Happened

Actuate Therapeutics (NASDAQ:ACTU) shares traded up 0.8% during mid-day trading on Monday . The stock traded as high as $9.08 and last traded at $8.69. 73,427 shares traded hands during trading, an increase of 55% from the average session volume of 47,485 shares. The stock had previously closed at $8.62.

Actuate Therapeutics Stock Up 0.8 %

The company’s 50 day moving average is $8.38.

Actuate Therapeutics (NASDAQ:ACTU) last posted its earnings results on Tuesday, September 24th. The company reported ($4.20) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Actuate Therapeutics

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC bought a new position in Actuate Therapeutics (NASDAQ:ACTU) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned approximately 0.06% of Actuate Therapeutics at the end of the most recent quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.